Her main field of interest is translational research and clinical development of novel therapeutic approaches in the treatment of solid tumors, particularly breast cancers. Projects in which she is involved are intended to identify molecular and cellular determinants predictive of response or toxicity to the new compounds in the context of personalized medicine.